Kintor prepping submissions of COVID-19 pill after Phase III readout

Kintor’s shares doubled Wednesday, recovering much of the value the company had lost in December, after data from a Phase III study showed that proxalutamide protected COVID-19 patients against hospitalization or death.

The China-based company said that of the trial’s patients with mild-to-moderate COVID-19 who received proxalutamide or placebo for at least seven days (n=693), none were hospitalized in the treatment arm, compared with six hospitalizations and one death in the study’s placebo arm. The 1:1 randomized study evaluated proxalutamide or placebo, in conjunction with standard-of-care; all but six of the 733 subjects recruited were in the U.S...